Brusterhaltende Therapie des Mammakarzinoms nach Augmentation mit injiziertem hydrophilem Polyacrylamidgel und Literaturübersicht

Abdallah, Abdallah; Wesemann, Alena; Saklaoui, O.; Stückle, C. A.; Sommerer, Florian; Zink, Matthias Daniel; Papadopoulos, Sarantos

doi:10.1159/000184444

Cited by 2 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, if gel remnants are still present, this may challenge future breast imaging. Recently published case reports also describe cases of breast cancer in women after PAAG injection and assume a possible association [21–23].…”

Section: Discussionmentioning

confidence: 99%

Polyacrylamide Gel Injections for Breast Augmentation: Management of Complications in 106 Patients, a Multicenter Study

et al. 2011

View full text Add to dashboard Cite

Injections of PAAG can cause irreversible damage to the breast necessitating complex debridement procedures, even mastectomy and breast reconstruction. Despite numerous surgical interventions, gel remnants are still found on subsequent breast imaging. Although PAAG is prohibited in many countries, different types of injections with unknown long-term effects are currently being used. Making the public aware of the problems of injectables for breast augmentation is warranted.

show abstract

Section: Discussionmentioning

confidence: 99%

Polyacrylamide Gel Injections for Breast Augmentation: Management of Complications in 106 Patients, a Multicenter Study

et al. 2011

View full text Add to dashboard Cite

show abstract

Bilateral breast cancer following augmentation mammaplasty with polyacrylamide hydrogel injection: A case report

Zhao

Yuan

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

Abstract. Breast cancer occurring following injection with polyacrylamide hydrogel (PAMG) for augmentation mammaplasty is rare. The present study reports the case of a 43-year-old female presenting with bilateral breast cancer 10 years after augmentation mammaplasty with PAMG injection and no family history of breast cancer. A 5.5x6.0-cm mass in the right breast with multiple intumescent axillary lymph nodes was revealed and a palpable mass of ~1.0 cm was identified in the outer upper quadrant of the left breast. Multiple smaller nodules were observed in the pulmonary field. Pathological examination revealed invasive lobular grade II carcinoma in both breasts with ER(+++), PR(+++), C-erbB2(-), Top-2(+), in the right breast and ER(++), PR(++), c-erb-B2(-), Top-2(+) in the left. Preoperative chemotherapy, modified radical bilateral mastectomy with axillary clearance, postoperative chemotherapy, and an oophorectomy were conducted, followed by treatment with Arimedex® until the present date A number of valuable insights can be garnered from this case. First, close follow-up is required for female patients who receive an injection of PAMG for augmentation mammaplasty in order to achieve an early diagnosis and to intervene in any incidences of breast cancer. Second, the differential diagnosis of dual primary carcinoma versus metastatic breast cancer is important and may be aided by the use of molecular technology. Third, it remains difficult to determine gene expression values for the prediction of chemotherapy sensitivity. Thus, discrimination between primary and secondary carcinomas is the principle barrier for identifying an appropriate treatment strategy when a patient is diagnosed with bilateral breast cancer.

show abstract

Brusterhaltende Therapie des Mammakarzinoms nach Augmentation mit injiziertem hydrophilem Polyacrylamidgel und Literaturübersicht

Cited by 2 publications

References 13 publications

Polyacrylamide Gel Injections for Breast Augmentation: Management of Complications in 106 Patients, a Multicenter Study

Polyacrylamide Gel Injections for Breast Augmentation: Management of Complications in 106 Patients, a Multicenter Study

Bilateral breast cancer following augmentation mammaplasty with polyacrylamide hydrogel injection: A case report

Contact Info

Product

Resources

About